Cardiff, UK – Diurnal Limited, the global specialty pharmaceutical company developing therapies for chronic endocrine diseases, is pleased to announce that Peter Allen has been appointed as Director and Chairman of the Board with immediate effect.
Peter has extensive experience in the healthcare industry, having held key senior positions in a number of organisations, and has a strong track record of success as a non-executive director and chairman in the biotech and specialty pharma industries.
Peter served both as Chairman and interim Chief Executive Officer of ProStrakan Group plc prior to its 2011 acquisition by Kyowa Hakko Kirin Co. Ltd., and spent three years as Chairman of Proximagen Neurosciences plc leading up to its 2012 acquisition by Upsher-Smith Laboratories. Between 1992 and 2004, Peter was Chief Financial Officer of Celltech Group plc where, in addition to managing the company’s flotation on the Main Market of the London Stock Exchange, he played a key role in the strategic acquisitions of Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. From 2003, Peter served as Deputy Chief Executive Officer of Celltech until its sale to UCB S.A. in 2004. Peter is currently Non-Executive Chairman of Advanced Medical Solutions plc, Clinigen plc, Future plc and Oxford Nanopore Technologies Limited.
Peter assumes the role of Chairman from Dr Sam Williams, who has been serving as Chairman on an interim basis and will continue as a Non-Executive Director.
Martin Whitaker, CEO of Diurnal, stated:
“I am delighted to welcome Peter to the Board of Diurnal. Peter is an experienced industry professional who has overseen or been involved in companies at every stage of the specialty pharma life cycle, including research, development, marketing and sales. This makes him ideally suited to the role of Chairman of Diurnal as we move towards the commercialisation of our highly specialised products for the treatment of chronic endocrine diseases.”
Peter Allen said:
“I am very excited about the opportunity that Diurnal has to become one of the leading specialty pharma companies in the field of endocrinology. Its combination of late-stage products, specialist markets and limited competition is a rarity in the UK sector and I look forward to helping the company to achieve all of its goals.”
Please direct all enquiries to:
Martin Whitaker, CEO
+44(0)871 716 8848